208036-32-2

Basic information

• Product Name: (E)-methyl 3-(3-fluoro-4-formylphenyl)acrylate
• Synonyms: (E)-methyl 3-(3-fluoro-4-formylphenyl)acrylate
• CAS NO: 208036-32-2
• Molecular Weight: 208.189
• Mol File: 208036-32-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (E)-methyl 3-(3-fluoro-4-formylphenyl)acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-methyl 3-(3-fluoro-4-formylphenyl)acrylate(208036-32-2)
• EPA Substance Registry System: (E)-methyl 3-(3-fluoro-4-formylphenyl)acrylate(208036-32-2)

Safety Data

• Hazardous Substances Data: 208036-32-2(Hazardous Substances Data)

Upstream product

• 292638-85-8 acrylic acid methyl ester 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 

Relevant articles and documents

3-substituted acrylic acid compound as well as preparation method and application thereof

The invention provides a 3-substituted acrylic acid compound as well as a preparation method and application thereof and in particular relates to a 3-substituted acrylic acid compound, a stereoisomer,a pro-drug, a hydrate or pharmaceutically acceptable salt or ester thereof, and a pharmaceutical composition thereof as well as a preparation method and application thereof. The compound provided bythe invention can inhibit activity of an estrogen receptor, regulate expression level of the estrogen receptor down or induce degradation of the estrogen receptor and can be used for preventing or treating diseases related to overactivity of the estrogen receptor, especially estrogen receptor positive (ER+) drug-resistant diseases (such as breast cancer producing drug resistance to anti-estrogen therapy).

CHEMICAL COMPOUNDS

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description: processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Hydroxamate-Based Inhibitors of Deacetylases

The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, R4, R5, ring A, and Z are as defined herein.